Evidence map›Paper›PMID 40192836›Full record

ArticleCellular and molecular life sciences : CMLS2025

Loss of NgBR causes neuronal damage through decreasing KAT7-mediated RFX1 acetylation and FGF1 expression.

Yuwei Hu, Yanni Ma, Lele Liu, Yan Hong, Guanghui Wang, Beisha Tang, Jifeng Guo, Peng Yang, Ying Cao, Haigang Ren

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuwei HuDepartment of Pharmacy, The Affiliated Zhangjiagang Hospital of Soochow University, Laboratory of Molecular Neuropathology, Department of Pharmacology, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, 215123, China.
Yanni MaDepartment of Pharmacy, The Affiliated Zhangjiagang Hospital of Soochow University, Laboratory of Molecular Neuropathology, Department of Pharmacology, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, 215123, China.
Lele LiuDepartment of Pharmacy, The Affiliated Zhangjiagang Hospital of Soochow University, Laboratory of Molecular Neuropathology, Department of Pharmacology, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, 215123, China.
Yan HongDepartment of Pharmacy, The Affiliated Zhangjiagang Hospital of Soochow University, Laboratory of Molecular Neuropathology, Department of Pharmacology, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, 215123, China.
Guanghui WangDepartment of Pharmacy, The Affiliated Zhangjiagang Hospital of Soochow University, Laboratory of Molecular Neuropathology, Department of Pharmacology, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, 215123, China.
Beisha TangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jifeng GuoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Peng YangJiangsu Provincial Medical Innovation Center of Trauma Medicine, Institute of Trauma Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215123, China. yangpeng@suda.edu.cn.
Ying CaoDepartment of Pharmacy, The Affiliated Zhangjiagang Hospital of Soochow University, Laboratory of Molecular Neuropathology, Department of Pharmacology, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, 215123, China. caoyaoshi@126.com.
Haigang RenDepartment of Pharmacy, The Affiliated Zhangjiagang Hospital of Soochow University, Laboratory of Molecular Neuropathology, Department of Pharmacology, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, 215123, China. rhg@suda.edu.cn.ORCID http://orcid.org/0000-0001-8844-4754

Funding

Key Laboratory in Science and Technology Development Project of Suzhou SZ2024001MOE Key Laboratory of Geriatric Diseases and Immunology JYN202401National Natural Science Foundation of China 32170987, 32471047National Natural Science Foundation of China 32271039Science and Technology Support Program of Jiangsu Province CXZX202231Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases, the Interdisciplinary Basic Frontier Innovation Program of Suzhou Medical College of Soochow University YXY2303023
6 · The paper itself

Abstract

Parkinson's disease (PD) is a common neurodegenerative movement disorder characterized by dopaminergic neuron loss in the substantia nigra pars compacta and striatal dopamine depletion. The NUS1 gene, which encodes the neurite outgrowth inhibitor B receptor (NgBR), has been recently identified as a novel risk gene for PD. However, its roles and mechanism in neurodegeneration are still unclear. Here, we demonstrate that NgBR deficiency triggers neuronal damage through a novel KAT7/RFX1/FGF1 axis. RNA sequencing and experimental verification revealed that NgBR depletion downregulates expression and secretion of fibroblast growth factor 1 (FGF1), which led to inactivation of the PI3K/AKT signaling pathway. Mechanistically, NgBR deletion suppresses lysine acetyltransferase 7 (KAT7) expression, impairing KAT7-mediated acetylation of regulatory factor X1 (RFX1), a transcriptional repressor for FGF1. This stabilized RFX1 by blocking its proteasomal degradation, thereby suppressing FGF1 transcription. Crucially, exogenous FGF1 rescued AKT signaling and mitigated neuronal damage in NgBR-deficient models. Our findings establish NgBR-KAT7-RFX1 as a regulatory axis controlling FGF1-dependent neuroprotection, which promotes the understanding of PD pathogenesis and highlights FGF1 supplementation as a potential therapeutic strategy.

Indexed as

Fibroblast Growth Factor 1Histone AcetyltransferasesNeuronsRegulatory Factor X1AcetylationAnimalsHumansMiceMice, Inbred C57BLParkinson DiseasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionFibroblast Growth Factor 1Histone AcetyltransferasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRegulatory Factor X1Rfx1 protein, mouseAcetylationFGF1Neuronal damageNUS1/NgBRParkinson’s diseaseRFX1

Identifiers

PMID40192836
PMCPMC11977062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.